1. Exogenously applied acetylcholine (ACh) is a modulator of human myoblast fusion. Using a chemiluminescent method, we examined whether an endogenous ACh-like compound (ACh-lc) was present in, and released by, pure human myogenic cells. 2. Single, freshly isolated satellite cells and proliferating myoblasts contained 15 and 0 5 fmol ACh-lc, respectively. Cultured myotubes contained ACh-lc as well. Also, ACh-like immunoreactivity was detected in all myogenic cells. 3. Part of the ACh-lc was synthesized by choline acetyltransferase (ChAT), as indicated by the reduction of ACh-lc content when bromoACh was present in the culture medium, and by direct measurements of ChAT activity. Also, ChAT-like immunoreactivity was observed in all myogenic cells.
4. Myoblasts and myotubes released ACh-lc spontaneously by a partially Ca2P-dependent mechanism. 5. The application by microperfusion of medium conditioned beforehand by myoblasts (thus presumably containing ACh-lc) onto a voltage-clamped myotube induced inward currents resembling ACh-induced currents in their kinetics, reversal potential, and sensitivity to nicotinic antagonists.
6. In vitro, the spontaneously released ACh-lc promoted myoblast fusion but only in the presence of an anticholinesterase. 7. Our observations indicate that human myogenic cells synthesize and release an ACh-lc and thereby promote the fusion process that occurs in muscle during growth or regeneration.
In the accompanying paper it is shown that cholinergic agonists acting on nicotinic receptors increase the rate of human myoblast fusion (Krause, Hamann, Bader, Liu, Baroffio & Bernheim, 1995) . The source of acetylcholine (ACh) that might act on myoblasts during muscle growth or regeneration in vivo, however, remains unknown; possible sources could be the muscle satellite cells, the proliferating myoblasts or the muscle fibres themselves. Indeed, it has been reported that a fraction of the ACh recovered in skeletal muscle is not linked to the nerve-ending compartment. Measurement of ACh content performed several weeks after muscle denervation indicated that 10-25% of the amount of ACh originally present in innervated muscle was still detectable at that time (Hebb, 1962; Miledi, Molenaar & Polak, 1977; Miledi, Molenaar, Polak, Tas & van der Laaken, 1982) . Under these conditions, the intracellular content of ACh was similar to that detected in nerve-free segments of muscle (Miledi et al. , 1982 . Furthermore, after denervation the activity of the ACh-synthesizing enzyme choline acetyltransferase did not decrease to zero, as would have been expected if ACh synthesis had been localized exclusively in nerve terminals (Hebb, Krnjevic & Silver, 1964 ). An explanation was that the extraneural ACh was associated with Schwann cells which can release ACh (Dennis & Miledi, 1974) . Another possibility, however, suggested by Miledi et al. (1977) , was that the muscle fibres contained and released ACh, but this has never been demonstrated, as the whole muscle is made up of several cell types. In cultured chick embryonic myoblasts the presence of the ACh synthesizing enzyme choline acetyltransferase (ChAT) has been documented (Entwistle, Zalin, Warner & Bevan, 1988b) . The same study showed evidence of ACh-like immunoreactivity. It was also suggested on the basis of indirect arguments that t To whom correspondence should be addressed. an ACh-like agent was released, but the source of this compound could not be ascertained, as the cultures contained non-muscle cells.
As we can prepare pure cultures of human satellite cells (Baroffio, Aubry, Kaelin, Krause, Hamann & Bader, 1993) , we examined whether an ACh-like compound (ACh-lc) was present in purified freshly isolated human satellite cells and in pure cultures of proliferating myoblasts and myotubes. These clonal cultures, derived from single satellite cells, are devoid of non-muscle cells. Significant levels of ACh-lc were found at the three stages of maturation studied, both with a chemiluminescent assay (Israel & Lesbats, 1981) Dissociation and culture procedure
Dissociation procedure was performed as described previously (Barofflo et al. 1993) . Briefly, the muscular tissue was cleaned and minced in 0 05% trypsin. The muscle biopsy was then digested in 0 05% trypsin for 1 h at 37 'C. Digestion was blocked by adding 15% (v/v) of fetal calf serum (FCS). The cell suspension was successively centrifuged to pellet the muscular debris. A Tris-ammonium chloride buffer was added to lyse red blood cells. Cells were then resuspended in a proliferation medium in which they actively proliferate as mononucleated myoblasts. The proliferation medium was composed of the nutrient medium FIO supplemented with 15% FCS and serum-free elements i.e. 0 5 mg ml-' bovine serum albumin (BSA), 0 5 mg ml-fetuin, 10 ng ml-' epidermal growth factor, 0 39 mg ml-' dexamethasone, 0.18 mg ml-' insulin, and 0 1 jug ml-' gentamicin. Formation of myotubes is induced by substituting the proliferation medium with a differentiation medium, composed of Dulbecco's modified Eagle's medium (DMEM) supplemented with 0 5 mg ml-' BSA, 10 ng ml-' epidermal growth factor, 10 #g ml-' insulin and 1 jcg ml-' gentamicin. Half of the culture medium was changed 3 times a week.
Clonal culture Single cells in suspensions were manually collected with a micropipette under a microscope, and cultured individually in 96-well culture dishes containing proliferation medium.
Flow cytometry
Flow cytometry analysis and sorting was done as previously described (Baroffio et al. 1993 (Widmer, Hamann, Baroffio, Bijlenga & Bader, 1995) . ACh was detected using the chemiluminescent method described by Israel & Lesbats (1981) Tucek, 1982 Assay of ChAT activity ChAT activity was determined using the isotopic method described by Fonnum (1969) . Cells in plastic wells of 1 cm diameter were rinsed twice with PBS (pH 7 4) before being removed from the bottom of the well by gentle scraping. Cells from three wells were then collected in an Eppendorf tube and centrifuged for 5 min at 500 g. The supernatant was removed and the pellet was dispersed in 40 ,ul of PBS buffer (NaH2PO4/Na2HPO4, 0 05 M, pH 7 4) containing 0-2% Triton X-100. Cells were sonicated and 10 #1 of the homogenate were added to 10 #1 of PBS (NaH2PO4/Na2HPO4, 0 05 M, pH 74) containing 02M NaCl, 2mm phenanthroline, 0-2% BSA and 0-2 mM physostygmine. Protein content The protein content in each sample was determined using the colorimetric procedure of Lowry, Rosebrough, Farr & Randall, (1951) . Bioassay A superfusion solution (see below) was added for 2 h to a 60 mm Petri dish containing a clonal culture of proliferating myoblasts. This conditioned medium was then filtered (pore size, 22 4um) and applied on myotubes using a computer-controlled application system (Krause et al. 1995) . In order to examine the effects of curare and a-bungarotoxin, these drugs were directly added to the bath perfusion. Patch clamp recordings made in the whole-cell configuration (Hamill, Marty, Neher, Sakmann & Sigworth, 1981) were performed with the Axopatch-200A amplifier (Axon Instruments; for details, see Krause et al. 1995) . Low-resistance electrodes (2-5 MQ2) were prepared from borosilicate tubing (Pyrex, Switzerland) with a two-stage puller (BB-CH, Mecanex, Switzerland). The cell membrane capacitance was obtained from direct reading of the potentiometer of the amplifier and this value was subsequently used to calculate the density of the current in pA pF-. The series resistance was usually less than 4 MQ. Currents were sampled at 1-7 kHz and low-pass filtered at 1 kHz. Acquisition of data was performed with the program DATAC (Bertrand & Bader, 1986 Figure 1 . Presence of ACh-lc in freshly isolated satellite cells A, flow cytometry analysis obtained from a freshly dissociated muscle biopsy. The suspension was analysed in forward light scatter (linear scale, size) vs right-angle light scatter (log scale, nucleocytoplasmic ratio). Isodensity lines of the contour plot define the presence of two populations of cells. The satellite cell population (SC) differs by the lower size and nucleocytoplasmic ratio (arrow) of the cell. B, example of a recording from the chemiluminometer obtained on a satellite cell extract from vastus lateralis muscle, 12 h after sorting. Peaks 1, 2 and 3 were obtained with the blank sample (see Methods) and peaks 4 and 5 were obtained with the biological sample. The artifacts at the baseline level before the arrows 1 and 4 were due to the automatic control of the carousel containing the two different samples. The first step of the procedure consisted of injecting AChE into the blank sample (arrow 1) after a stable baseline, due to the endogenous choline content, was reached (not shown). This injection of AChE elicited only a small peak of light as this sample was previously inactivated (see Methods). Then, an ACh standard of 20 pmol was injected into the sample (arrow 2) followed by a new injection of AChE (arrow 3). The value obtained for peak 3 was comparable to that obtained for peak 1, indicating that all the ACh present in the standard was totally hydrolysed and that the quantity of AChE injected was sufficient. The second step of the procedure was performed on the biological sample. After stabilization of the baseline (not shown), AChE was injected into the biological sample at arrow 4, followed by a new injection of AChE (arrow 5) in order to ensure that all ACh-lc contained in the sample has been hydrolysed. ACh-lc content, calculated as described in Methods, was 17 pmol for this aliquot. When extrapolated to the total suspension containing 20 000 cells, the ACh-lc content was 144 pmol. Fig. 2A and B) . Satellite cells were heavily labelled in contrast to nonmyogenic cells, presumably fibroblasts (see Baroffio et al. 1993) (Fig. 2D) . ACh-li was also present in proliferating myoblasts (Fig. 2F) and myotubes (Fig. 2H) . Controls performed by omission of the primary antibody are illustrated in Fig. 2C , E, G and I for satellite cells, nonmyogenic cells, proliferating myoblasts and myotubes, respectively.
Anticholinesterase increases ACh-lc contents The possible presence of AChE may affect ACh measurements (Toutant & Massoulie, 1988) . We observed that the addition of an AChE inhibitor (10 uM phospholine) increased the recovery of ACh-lc both in proliferating myoblasts and in myotube cultures. The addition of phospholine on proliferating myoblasts for 30 min before the ACh assay significantly increased (P < 0-001) the ACh-lc content from 16 + 1 to 87 + 3 pmol well-' (n = 4).
In myotubes, the ACh-lc content increased (P < 0-001) ACh-like compound in human myogenic cells Role of choline acetyltransferase The synthesis of ACh-lc could be due to the ACh synthesizing enzyme ChAT, or to non-specific enzymes, for example carnitine acetyltransferase. The possible involvement of ChAT was tested by adding the selective blocker, bromoACh, to the culture medium (see Tucek, 1982 ). In all clones tested, the amount of ACh-lc decreased when 2 /tM bromoACh was added 48 h before the assay. In proliferating myoblasts (4 samples, 1 clone), ACh-lc decreased from 81 + 3 to 64 + 1 pmol well-' (P = 0-0017).
In myotubes (11 samples, 5 clones), ACh-lc decreased from 146 + 7 to 48 + 8 pmol well-' (P < 0-001). This result suggests that at least part of the synthesis of ACh-lc is due to ChAT. Furthermore, as these two values are significantly different, it suggests that the contribution of ChAT is more important in differentiated cultures.
Using [14C] acetylCoA, the activity of ChAT was confirmed in both myoblast and myotube cultures (2 clones tested), with a maximum rate of synthesis (in nmol h-' (mg protein)-') of 10 + 1 in myoblasts (n = 8) and 18 + 1 in myotubes (n = 9), indicating also that myotubes have a significantly greater ChAT activity than myoblasts (P < 0-001). Note that these values are somehow higher than those reported in L6 rat myoblasts (Schubert et al. 1974 (Fig. 3A) , in clonal cultures of myoblasts (Fig. 3B) and in myotubes (Fig. 3C) . The presence of ChATli was demonstrated in seven different clones maintained either in proliferation or differentiation media. The specificity of ChAT immunolabelling was assessed by controls made in the absence of the ChAT antibody ( Fig. 3D and G) . In this condition, only a slight staining was observed, corresponding to background noise. Furthermore, ChAT-li was not expressed in fibroblast-like cells (Fig. 3E) .
ACh-le is released from proliferating myoblasts and myotubes As myoblasts and myotubes contained ACh-lc, we wondered whether these cells could release it into the extracellular medium. One clonal culture was washed with PBS and 250 #1 fresh PBS was added to each well in the absence of an AChE inhibitor for 15 min at 37 'C. The supernatant was then removed and aliquots of 50 #1 were directly added to the chemiluminescent reaction mixture for ACh-lc determination. The amount of ACh-lc present in the PBS after 15 min was 112 + 9 pmol (n = 4) for proliferating myoblasts and 47 + 20 pmol (n = 4) for myotubes, corresponding to concentrations of 448 + 36 and 188 + 80 nm, respectively. Intracellular levels of ACh-lc measured for myoblasts and myotubes at the end of the 15 min incubation period were respectively 66 + 7 and 71 + 13 pmol. Thus, the amount of ACh-lc collected in PBS during the 15 min period exceeded the amount present inside the cells at the end of the release experiment. All these measurements were performed in the presence of 1 mM calcium in the extracellular medium. Exposure of proliferating myoblasts and myotubes to low extracellular calcium decreased the amount of ACh-lc released in a similar way in myoblasts and in myotubes. Pooling the data from the two preparations, we found that low calcium significantly decreased (P < 0 001) the ACh-lc from 47 + 1 to 23 + 2 pmol well-' (n = 16). Thus, the release of ACh depends at least in part on the presence of extracellular calcium.
A ACh-lc release was also tested by exposing voltage-clamped myotubes to a conditioned medium that was collected after 2 h incubation on proliferating myoblasts. We found that eleven myotubes tested (2 clones) responded to the application of the conditioned medium with a mean inward current of 1P5 + 0'6 pA pF-1 at -80 mV (mean capacitance of 360 + 60 pF). Figure 4A illustrates a whole-cell recording from a inyotube exposed to conditioned medium for 800 ms and held at different voltages between -80 and 0 mV. The reversal potential of the current induced by the conditioned medium (3 + 2 mV; n = 3) was not O r . Whole-cell recording of a myotube exposed for 800 ms to a conditioned medium The conditioned medium (see Methods) was collected after 2 h of exposure to a clonal culture of proliferating myoblasts. A, the myotube was held at voltages between -80 and 0 mV (increments of 20 mV are illustrated). In the inset, the maximum current was plotted as a function of the membrane potential. The reversal potential was estimated to be +8 mV by fitting the data using a linear regression. B, the myotube was held at -80 mV and the current induced by application of the conditioned medium was recorded first in control, then in 50 AM curare and again in control (wash) conditions. C, the myotube was held at -80 mV and the current was recorded first in control, then in the presence of 10 jaM a-bungarotoxin (ac-BuTX) and again in control (wash) conditions. All data are from the same myotube (220 pF) and are leak-subtracted. The ACh-lc content in the conditioned medium evaluated by chemiluminescent assay was 70 nm. 798 J Physiol. 489.3 significantly different (P = 0 3) from that of the AChinduced current in human myotubes (see Table 1 , Krause et al. 1995) . Moreover, the current was abolished by 50 ,C4M curare and by 10 /LM a-bungarotoxin ( Fig. 4B and C Physostygmine increases the fusion of myoblasts Physostygmine was added to the differentiation medium and the fusion index was assessed in cultures exposed to differentiation medium for 2 days. A, percentage increase in the fusion index as a function of physostygmine concentration. The 0 % value corresponds to the fusion index observed, at the same time, in the absence of physostygmine. At concentrations of physostygmine greater than 1 fiM, small myoballs formed in the culture and sometimes detached, precluding accurate measurement of the fusion index. B, the effect of 100 nm physostygmine on the fusion index is inhibited by 2 FM a-bungarotoxin (a-BuTX). ACh-like compound in human myogenic cells M. Hamann 
and others
AChE increases the rate of fusion Our accompanying paper (Krause et al. 1995) showed that the activation of ACh receptors by carbachol application enhances the rate of fusion of human myoblasts and that this effect is selectively blocked by the nicotinic ACh receptors blockers a-bungarotoxin and curare. In view of our results demonstrating that human myoblasts themselves can release ACh-lc we examined whether the spontaneous fusion process occurring in differentiation medium could be affected by cholinergic antagonists, as this would indicate that the ACh-lc released promotes fusion in vitro. Proliferating myoblasts were cultured in differentiation medium containing either 5 /uM curare or 5 J#M a-bungarotoxin and the fusion index was evaluated after 3 days in differentiation medium (see Methods). At these concentrations, the blockers significantly reduced the effect of carbachol (see Krause et al. 1995) but failed to affect the fusion in the absence of carbachol. Three clones were tested and the fusion index in the presence of 5 ,CM curare (37 + 2 %) or 5 Cmi a-bungarotoxin (40 + 2 %) was not significantly different from control (39 + 2%; P = 0 5 and P = 0-8, respectively). It is worth mentioning that in our experiments, after 3 days in differentiation medium the absence of effect of the nicotinic antagonists cannot be explained by a saturation of the fusion index, as the maximum fusion index was usually reached after 7 days (Widmer et al. 1995) . The absence of effect of nicotinic antagonists under basal conditions in our cultures may be explained by the presence of AChE in or at the surface of myoblasts (Elson, Gentry & Doctor, 1992) . Consequently one would predict that under conditions in which AChE is inactivated, higher levels of ACh-lc should be present in the extracellular medium. Figure 5A indicates that physostygmine increases the fusion of myoblasts in a dose-dependent way from 10-8 to 10-6 M. The fusion-promoting effect of 100 nM physostygmine was significantly (P < 0-001) inhibited by 2 JCM a-bungarotoxin (Fig. 5B) . Some anti-AChEs, in the micromolar range, are described as acting as partial agonists of the nicotinic ACh receptor (Bakry, El-Rashidy, Eldefrawi & Eldefrawi, 1988) . In preliminary experiments, phospholine was used as an esterase inhibitor, but this was abandoned when we found that phospholine was acting as a 'partial agonist', inducing small inward currents (50-100 pA at -80 mV) when applied on myotubes (data not shown). To exclude the possibility that the effect on the fusion index seen in Fig. 5A was due to a direct action of physostygmine (0-1 nM-1 /lM) on cholinergic receptors, we applied a solution containing 1 ,UM physostygmine on four voltageclamped myotubes and checked for activation of inward currents. No detectable responses were produced whereas large responses in the nanoamp range were induced by the application of 1 ,UM carbachol on the same cells (data not shown). Thus, these results indicate that the increase of cell fusion observed with anti-AChE was specifically due to inactivation of the AChE leading to a rise in ACh-lc levels.
DISCUSSION
The aim of this study was to examine whether ACh, a modulator of myoblast fusion (Krause et al. 1995) , was present in freshly isolated human muscle satellite cells and in pure cultures of proliferating myoblasts and myotubes.
The clonal human satellite cell preparation eliminates possible complications associated with the presence of nonmuscle cells, as flow cytometry analysis and sorting allows us to obtain pure suspensions of freshly isolated satellite cells. Using a sensitive chemiluminescent technique, we found that an ACh-like compound (ACh-lc) was present in muscle at the three different stages of maturation studied. In addition, ACh-lc was detected in the extracellular solution of both proliferating myoblast and myotube cultures, suggesting a spontaneous release of ACh-lc by these cells.
As previously described by Israel & Lesbats (1981) , the chemiluminescent method is well suited to the detection of small amounts of ACh (sensitivity of about 2 pmol) and its specificity has been confirmed, as even in the presence of ACh no light could be recorded when choline oxidase and AChE were omitted (Palouzier-Paulignan et al. 1992 (Hebb et al. 1964) , and in nerve-free segments of muscle (Hebb et al. 1964; . Thirdly, spontaneous release of ACh from denervated muscles was mentioned (Mitchell & Silver, 1963 (1974) estimated that the amount of ACh in a Schwann cell was in the order of only 10-16 mol. Such an amount would represent only about 5% of the ACh actually found in the denervated end-plate segments. Although the matter is not settled, one other source of ACh could be the muscle fibres themselves, or other cells in the muscle, which after denervation still contain a substantial amount of ACh. The observation reported here that purified suspensions of freshly isolated, non-dividing satellite cells contain ACh-lc suggests that the native satellite cells that rest on skeletal muscle fibres (Campion, 1984) contain ACh. Moreover, the release experiments performed on clonal cultures of proliferating myoblasts and myotubes showed that the synthesized ACh-lc was secreted by both types of cells. These results indicate that synthesis and release of ACh-lc can occur in pure cultures of myotubes and suggest that a substantial fraction of the ACh observed in denervated muscle is of myogenic origin. Synthesis of ACh-lc Immunocytochemical detection of ChAT-like immunoreactivity in freshly isolated satellite cells and proliferating myoblast and myotube cultures suggests that this enzyme might be involved in the ACh-lc synthesis of these cells.
ChAT expression was also observed in myoblasts and myotubes of chick embryos after 2-3 days in culture (Entwistle et al. 1988 b) as well as in tongue myoblasts co-cultured with dissociated hypoglossal motoneurones (Ternaux & Portalier, 1993) . ChAT activity was also measured in the rat muscle cell line L6 (Schubert et al. 1974) . Here, we report for the first time the presence of ChAT in human muscle satellite cells. In the present study, the addition of bromoACh to myoblast and myotube cultures led to a decrease of ACh-lc content in both types of cultures, further suggesting that ACh-lc synthesis was in part due to the activity of the ChAT. Moreover, ChAT activity was confirmed by a specific assay (Fonnum, 1969) in both proliferating myoblast and myotube cultures. On the basis of bromoACh experiments and measurement of ChAT activity, it appears that the contribution of ChAT to ACh synthesis was higher in differentiated cultures than in proliferating myoblasts. Previous studies performed on mammalian cardiac and skeletal muscle demonstrated that both ChAT and carnitine acetyltransferase were able to synthesize ACh with different saturation kinetics depending on choline concentrations (White & Wu, 1973) . In rat denervated skeletal muscle, only 2% of ACh was inhibited by 2 /M bromoACh (Tucek, 1982) (Dale, Feldberg & Vogt, 1936) . Katz & Miledi (1977) These cellular concentrations are within the range of the estimated free ACh levels (0 3-30 mM) found within cholinergic terminals (Katz & Miledi, 1977; Israel, Dunant & Manaranche, 1979 (Hille, 1992 (Dan & Poo, 1992) . Moreover, ultrastructural studies of Xenopus myocytes have demonstrated the existence of vesicles of various sizes which may serve to accumulate ACh (Buchanan, Sun & Poo, 1989) . Functional role of ACh A first intriguing observation is the high concentration of ACh-lc in freshly isolated satellite cells. This could occur if ACh-lc synthesis exists at a time when the release mechanism is not yet operating and when AChE activity is low. It is worth mentioning that nicotinic receptors were not found either on fibre-attached satellite cells from the rat during the first 24 h after dissociation (Bader, Bertrand, Cooper & Mauro, 1988) or on freshly isolated human muscle satellite cells (Krause et al. 1995) . In rat, as in human muscle satellite cells, these receptors only appear when myoblasts are proliferating (Bader et al. 1988; Krause et al. 1995) and their presence in proliferating mononucleated myoblasts has also been described by others (Eusebi & Molinaro, 1984; Siegelbaum, Trautmann & Koenig, 1984) . Therefore, if ACh-lc has any effect on human muscle satellite cells at the very early stages, it would have to be either through a mechanism involving receptors other than nicotinic receptors or indirectly, through ACh receptors located, for example, on muscle fibres. At later stages of myogenesis in chick embryo and postnatal human muscle, ACh was demonstrated to promote myoblasts fusion in vitro (Entwistle, Zalin, Bevan & Warner, 1988a; Entwistle et al. 1988b; Krause et at. 1995) . In the present study, the anticholinesterase physostygmine enhanced the spontaneous fusion process without acting as a partial agonist on ACh receptors. As this effect was suppressed by nicotinic receptor blockers, it suggests that the spontaneously released ACh-lc acts on the nicotinic receptors present on myoblasts and myotubes. In muscle, ACh increases activity of Na+,K+-ATPases (Dlouha, Teisinger & Vyskocil, 1979) , affects membrane potential (Bray, Forest & Hubard, 1982) , regulates expression of extrajunctional receptors (Pestronk, Drachman, Stanley, Price & Griffin, 1980) and controls transmitter release at the neuromuscular junction (Bowman, Marshall, Gibb & Harbone, 1988) . Furthermore, ACh is described as a trophic factor stimulating mitogenic activity in pulmonary neuroendocrine cells (Nylen, Tabassian, Becker, Cassidy & Linnoila, 1987) or acting on neurite elongation in the hippocampus, retina or buccal ganglia (McCobb, Cohan, Connor & Kater, 1988; Lankford, DeMello & Klein, 1988; Lipton, 1988; Mattson, 1988 ). The present study, which demonstrates the synthesis and release of an ACh-lc by pure human myogenic cells, suggests yet another function for ACh in human muscle: the modulation of the myoblast fusion process.
